AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 281 min read$BTMD

BTMD Q3'26 Earnings: revenue estimate is 44.01M USD

BTMD (Biote Corp.) will release Q3'26 earnings on November 04. Analysts expect $44.01M revenue and -$0.01 EPS. Results will be announced after market close.

Original reporting
tradingview.com
Published Oct 28, 2026, 11:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BTMD Q3'26 Earnings: revenue estimate is 44.01M USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$BTMDBearishMed
01

Why it matters

The preview sets expectations; investors may adjust positions ahead of the actual earnings release.

02

Market read

Earnings preview for a micro‑cap biotech; relevance primarily to BTMD shareholders and sector watchers.

03

What to watch

Potential upcoming catalyst such as a clinical trial readout not mentioned in the preview.

Relevance 6/10Novelty 7/10Timing: before market close on Nov 4

Background

BTMD (Biote Corp.) is a micro‑cap biotech scheduled to release Q3'26 results on Nov 4 after market close.

Company-level read

Ticker impact

$BTMDBearishMedium confidence
Context

Article provides the first public revenue and EPS estimates for BTMD's Q3'26 earnings, a material earnings preview for the micro‑cap.

Expected impact

likely downside as investors price in low EPS guidance

Evidence & confidence

44.01M revenue and $0.01 EPS are modest for a biotech; market typically reacts negatively to low guidance.

Market effects

Sector

Biotech sector may see slight pressure if BTMD's weak outlook influences peer expectations.

Regional

Limited to US micro‑cap investors; no broad regional effect.

Global

Minimal global impact due to small market cap.

Counterpoint

What could challenge this read

If the market overreacts to the low estimate, a bounce could occur on any positive trial news.

Key entities

  • Company
    Biote Corp.

    US‑listed biotech company (ticker BTMD).

Read at source← All news

Related articles

AUG 7
$BTMDMed

biote Q2 Earnings Call Highlights

Biote (NASDAQ: BTMD) reported Q2 net loss of $7.4M ($0.23/share) versus prior-year net income of $3.9M, and adjusted EBITDA of $5.6M (12.6% margin). Gross margin fell to 65.4% from 71.6% due to higher-cost third-party pellets during a disruption and $600k recall-related costs. Biote cut its 2026 outlook to revenue above $175M and adjusted EBITDA above $25M.

yahoo.com6 min
AUG 5
$BTMDMed

Biote Reports Second Quarter 2026 Financial Results

biote Corp. (BTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Biote Reports Second Quarter 2026 Financial Results Continued progress in advancing strategic initiatives Updates full-year outlook Second Quarter 2026 Financial Highlights • Revenue of $44.2 million • Gross profit margin of 65.4% • Net loss of $(7.4) million and diluted loss per

SEC EDGAR 8-K6 min
OCT 28
$CFFNMed

Capitol Federal Financial, Inc. (CFFN): REPORTS FOURTH QUARTER AND FISCAL YEAR 2026 RESULTS

Capitol Federal Financial, Inc. (CFFN) filed an SEC Form 8-K — Results of Operations and Financial Condition. NEWS RELEASE FOR IMMEDIATE RELEASE October 28, 2026 CAPITOL FEDERAL FINANCIAL, INC. ® REPORTS FOURTH QUARTER AND FISCAL YEAR 2026 RESULTS Topeka, KS - Capitol Federal Financial, Inc. ® (NASDAQ: CFFN) (the "Company," "we" or "our"), the parent company of Capitol Federal Savings Ba

SEC EDGAR 8-K2 min
OCT 28
$APHHighAI 9/10

AMPHENOL REPORTS RECORD THIRD QUARTER 2026 RESULTS

AMPHENOL CORP /DE/ (APH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ ​ ​ Amphenol News Release ​ World Headquarters ​ 358 Hall Avenue Wallingford, CT 06492 Telephone (203) 265-8900 ​ AMPHENOL REPORTS RECORD THIRD QUARTER 2026 RESULTS AND ANNOUNCES DIVIDEND INCREASE AND NEW STOCK REPURCHASE PROGRAM ​ Third Quarter 2026 Highlights:

SEC EDGAR 8-K3 min
OCT 28
Med

Zurn Elkay Q3 2026 slides: margins expand despite market headwinds

Zurn Elkay reported Q3 2026 net sales of $495M, up 9% YoY, with adjusted EBITDA margins expanding to 28.3%. Despite beating estimates, shares fell 5.6% due to cautious 2027 market outlook. The company highlighted strategic expansion into hot water systems and strong capital returns, including an 18% dividend increase and $135M in share repurchases.

investing.com2 min